$54.49▴ 0.55%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-496.43MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-40.7%year over year
Weak
Revenue is contracting year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Ionis Pharmaceuticals, Inc. is pre-profit. It is still burning cash while pre-profit. Revenue is contracting year over year.
Key numbers
Valuation
EPS (TTM)$-3.46
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin-64.7%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$874.09M
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days3 articles
1 bullish1 neutral1 bearish
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS
Oligonucleotide CDMO Market to Reach USD 9.87 Billion by 2031 as RNA-Targeted Drug Pipelines Expand
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.